A survey of Australian and New Zealand clinical practice with neoadjuvant systemic therapy for breast cancer

摘要: BACKGROUND Neoadjuvant systemic therapy (NAST) has become an established treatment option for women with operable breast cancer. AIM We aimed to better understand NAST patterns, barriers and facilitators in Australia New Zealand. METHODS undertook a cross-sectional survey of the current clinical practice Australian Zealand cancer specialists. Questions included referral patterns NAST, patient selection, logistics, decision making barriers. RESULTS Of 207 respondents, 162 (78%) reported routinely offering selected patients (median 9% offered NAST). Specialty, location, type, gender or years experience did not predict NAST. In all, 45 58% wanted increase number who receive routine care trials respectively. Facilitators multidisciplinary team meeting access trials. Specialist-reported included: desire immediate surgery (63% rated as important/very important); lack awareness (50%); concern about progression (43%) disinterest downstaging (32%). Forty-three per cent participants experienced system-related use including other clinicians' interest (27%); (24%) unacceptable wait medical oncology appointment (37%). CONCLUSION This group clinicians are interested Patient- that prevent optimal uptake this approach will need be systematically addressed if is more common approach.